NCT02762006View on ClinicalTrials.gov

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

November 6, 2020

Study Completion Date

November 6, 2020

Conditions
Renal Cell CarcinomaKidney Cancer
Interventions
DRUG

Durvalumab

Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.

DRUG

Tremelimumab

Tremelimumab is a CTLA-4 monoclonal antibody.

Trial Locations (2)

44195

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

Moshe Ornstein

OTHER

NCT02762006 - Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter